Walking program improves liver enzymes and BMI in children with PKU and NAFLD
A randomized controlled trial evaluated an 8-week free walking program versus waitlist control in 40 overweight/obese children aged 9-12 years with phenylketonuria (PKU) and non-alcoholic fatty liver disease (NAFLD). The study duration was 8 weeks. The primary outcome was not reported.
The main finding was a significant enhancement (improvement) in the exercise group only across multiple secondary outcomes: BMI, ALT, GGT, ALP, AST, and TG. The abstract reports the direction of effect as improvement but does not provide specific numerical results, effect sizes, p-values, or confidence intervals. The comparator was a waitlist control group.
Safety and tolerability data, including adverse events, serious adverse events, and discontinuations, were not reported in the abstract. Key limitations include the small sample size (n=40), short 8-week follow-up period, and lack of reported statistical measures and effect sizes. Funding sources and conflicts of interest were not reported.
For clinical practice, this single, small RCT suggests a walking intervention may benefit metabolic and liver parameters in this specific pediatric population over 8 weeks. However, the absence of numerical data and statistical measures precludes assessment of the magnitude of effect. These findings should be interpreted as preliminary evidence requiring validation in larger, longer-duration studies with complete outcome reporting before considering changes to clinical management.